Resource Center

Mar 16, 2017
  |  Poster

Mechanistic Modeling And Hepatic Biomarker Data From Ggf2 (Cimaglermin Alfa)-Treated Subjects In Phase 1 Clincial Trials Suggest Low Likelihood Of Progressive Liver Injury

Background

GGF2 (USAN cimaglermin alfa) is an investigational drug for the treatment of heart failure. During Phase 1 clinical trials, concomitant, transient elevations in serum aminotransferases (ALT/AST) and bilirubin meeting FDA DILI Guidance stopping criteria (Hy’s Law) were observed in two treated subjects but resolved within 2 weeks, with no further LFT abnormalities over the following 1-3 years. GGF2 has no direct toxic effect on human hepatocytes in vitro, so further exploration of these cases was undertaken.

American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2017 Annual Meeting, March 15-18, 2017,  Washington, DC

By Diane M. Longo, Grant T. Generaux, Brett A. Howell, Scott Q. Siler, Daniel J. Antoine, Donald Button, Anthony Caggiano, Andrew Eisen, Jennifer Iaci, Ric Stanulis, Paul B. Watkins

 

 

Contact Us About This Poster